Everything you need to win Neurogene — in one platform.
Who to reach, what to say, and why now on Neurogene — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Neurogene — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
The decision-maker’s email and mobile — dial in-browser.
Neurogene Announces Oversubscribed $200 Million Private Placement
Nov 04, 2024•over 1 year ago
Contract Type
partnership
New YorkBiotechnologyHealth CareTherapeutics
Description
Neurogene Inc. has announced an oversubscribed $200 million Private Investment in Public Equity (PIPE) financing, with participation from various investors. The financing is expected to provide runway into the second half of 2027 and support the completion of enrollment for NGN-401 for Rett syndrome, CMC scale-up, and further development of its gene therapy pipeline.
Company Information
Company
Neurogene
Location
New York, New York, United States
About
Neurogene Inc. is a clinical-stage company dedicated to bringing life-changing genetic medicines to patients and families affected by rare neurological diseases. The company focuses on developing novel approaches and treatments to overcome the limitations of conventional gene therapy in central nervous system disorders.
New YorkBiotechnologyHealth CareTherapeutics